Research programme: immunomodulators - EnGeneIC/Takeda
Alternative Names: Cancer therapeutics - EnGeneIC/TakedaLatest Information Update: 22 Sep 2023
At a glance
- Originator EnGeneIC; Takeda
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 22 Sep 2023 Discontinued - Preclinical for Cancer in Australia (IV), prior to September 2023 (EnGeneIC pipeline, September 2023)
- 28 Nov 2020 No recent reports of development identified for preclinical development in Cancer in Australia (IV, Injection)
- 09 Oct 2016 EnGeneIC and Takeda agree to co-develop immunomodulators in Australia for Cancer